Lupin

OverviewSuggest Edit

Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.

TypePublic
Founded1968
HQMumbai, IN
Websitelupin.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Apr 2022)18,573
Job Openings1
Revenue (FY, 2021)₹149.3 B(-10%)
Share Price (May 2022)₹600.5(+2%)
Cybersecurity ratingFMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Lupin

Manju D Gupta

Manju D Gupta

Chairman
Kamal K Sharma

Kamal K Sharma

Vice Chairman
Richard Zahn

Richard Zahn

Independent Director
K U Mada

K U Mada

Independent Director
Dileep C Choksi

Dileep C Choksi

Independent Director
Alan Butcher

Alan Butcher

Chief Corporate Development Officer
Show more

Lupin Office Locations

Lupin has offices in Mumbai, Ankleshwar, Aurangabad, Bhopal and in 11 other locations
Mumbai, IN (HQ)
Laxmi Towers BKC Road
Ankleshwar, IN
123, 1, GIDC, Ankleshwar GIDC
Aurangabad, IN
28, 1, MIDC Industrial Area, Chilkalthana
Bhopal, IN
Plot No 198-202, Ward Number 11, Hoshangabad Rd, Sector B, Nr, Mandideep
Boisar, IN
142, MIDC Rd, Tarapur M.I.D.C.
Dabhasa, IN
Block Street Number 21
Show all (18)

Lupin Financials and Metrics

Lupin Revenue

Lupin's revenue was reported to be ₹149.27 b in FY, 2021
INR

Revenue (Q3, 2022)

40.9b

Gross profit (Q3, 2022)

25.0b

Net income (Q3, 2022)

5.5b

EBITDA (Q3, 2022)

4.0b

EBIT (Q3, 2022)

2.0b

Market capitalization (26-May-2022)

293.8b

Closing stock price (26-May-2022)

600.5

EV

293.8b
Lupin's current market capitalization is ₹293.8 b.
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

155.5b163.7b166.0b149.3b

Cost of goods sold

(57.5b)(63.1b)(59.7b)(59.2b)

Gross profit

100.5b104.1b108.6b92.9b

R&D expense

(18.4b)(15.8b)(15.1b)(14.3b)
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Revenue

37.7b38.9b43.8b43.6b43.0b37.2b34.7b37.8b39.2b42.4b40.0b40.9b

Cost of goods sold

(14.4b)(13.9b)(16.0b)(15.5b)(15.3b)(13.6b)(12.9b)(13.8b)(13.7b)(15.3b)(16.3b)(16.9b)

Gross profit

26.0b27.9b29.5b29.4b29.6b25.0b22.8b24.8b26.6b27.7b25.3b25.0b

R&D expense

(3.8b)(3.8b)(425.7m)(3.8b)3.8b
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021

Cash

14.1b9.9b24.5b17.4b

Accounts Receivable

51.9b51.5b54.5b44.7b

Prepaid Expenses

5.1b5.2b6.8b2.9b

Inventories

36.6b38.4b34.6b40.9b
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Cash

10.9b11.6b13.2b12.8b

Accounts Receivable

52.0b49.2b48.0b43.1b

Prepaid Expenses

2.0b123.9m

Inventories

38.5b41.1b40.2b44.7b
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

5.5b15.2b7.6b16.8b

Depreciation and Amortization

10.9b10.9b11.6b8.9b

Inventories

172.7m(2.9b)(4.8b)(6.6b)

Accounts Payable

(305.8m)(1.6b)5.6b(3.7b)
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Net Income

4.4b6.3b(14.5b)

Depreciation and Amortization

6.4b4.3b11.3b

Inventories

(2.6b)(5.9b)(3.9b)

Accounts Payable

1.6b(206.0m)3.4b
INRFY, 2018

Revenue/Employee

9.3m
Show all financial metrics

Lupin Revenue Breakdown

Embed Graph

Lupin revenue breakdown by business segment: 100.0% from PHARMACEUTICAL

Lupin Cybersecurity Score

Cybersecurity ratingPremium dataset

F

55/100

SecurityScorecard logo

Lupin Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Lupin Online and Social Media Presence

Embed Graph

Lupin News and Updates

Global Intestinal Pseudo Obstruction Treatment Market Report 2022-2027 Featuring Pfizer, Cipla, GlaxoSmithKline, Teva., Eli Lilly and Co, Novartis, J&J, Dr. Reddy's Lab, F. Hoffmann-La Roche, Lupin

DUBLIN, May 20, 2022 /PRNewswire/ -- The "Global Intestinal Pseudo Obstruction Treatment Market, By Condition (Acute v/s Chronic), By Diagnosis (Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Others), By Treatment, By End User, By Region, Competitional...

Brokerages Cut Estimates For Lupin On U.S. Price Erosion, Cost Inflation

Here’s what brokerages have to say about Lupin’s fourth-quarter performance.

Lupin Q4 Review - Growth Contingent On Niche Launches, Cost Optimisation: Motilal Oswal

Lupin Q4 Review - Growth Contingent On Niche Launches, Cost Optimisation: Motilal Oswal

After Surprise Loss, Lupin Expects Much-Better Earnings In Second Half Of FY23

While Q4 is always a weaker quarter for India, the U.S. market was plagued with recalls and price erosion, says CFO Swaminathan.

Share Market Live: Sensex, Nifty Set To Fall; ITC, BPCL, Lupin, Adani Enterprises, IndiGo In Focus

Catch all live updates on share prices, index moves, corporate announcements and more from the Sensex and Nifty, today.

Stocks To Watch Today: BPCL, Dr Reddy's, IndiGo, ITC, Lupin, Ruchi Soya

Here are the stocks to watch going into trade today..
Show more

Lupin Frequently Asked Questions

  • When was Lupin founded?

    Lupin was founded in 1968.

  • Who are Lupin key executives?

    Lupin's key executives are Manju D Gupta, Kamal K Sharma and Richard Zahn.

  • How many employees does Lupin have?

    Lupin has 18,573 employees.

  • What is Lupin revenue?

    Latest Lupin annual revenue is ₹149.3 b.

  • What is Lupin revenue per employee?

    Latest Lupin revenue per employee is ₹8 m.

  • Who are Lupin competitors?

    Competitors of Lupin include Mito BioPharma, Sciwind and Tetra Therapeutics.

  • Where is Lupin headquarters?

    Lupin headquarters is located at Laxmi Towers BKC Road, Mumbai.

  • Where are Lupin offices?

    Lupin has offices in Mumbai, Ankleshwar, Aurangabad, Bhopal and in 11 other locations.

  • How many offices does Lupin have?

    Lupin has 18 offices.